Key points are not available for this paper at this time.
Initiating stiripentol in infants with Dravet syndrome is safe and beneficial, significantly reducing long-lasting seizures including status epilepticus, hospitalizations, and mortality in the critical first years of life.
Chiron et al. (Wed,) studied this question.